A Study on the Use of Topical Bepotastine Besilate Ophthalmic Solution (Bbos) 0.15% in the Treatment of Vernal Keratoconjunctivitis at Tertiary Care Hospital

Abstract

The aim of this study is to Evaluation of Efficacy and Safety of Bepotastine Besilate 0.15% Ophthalmic Solution in Patients of Vernal Keratoconjunctivitis (VKC). This was a prospective, open label and randomized clinical study. Fifty patients of vernal keratoconjunctivitis between 6 to 20 years of age of either sex willing to give informed consent were enrolled in the study. Patients received Bepotastine besilate (0.15%) eye drops twice daily for 8 weeks. Symptoms scoring and signs scoring of VKC were recorded on baseline and at the time of follow up at 4 and 8 weeks. Safety assessments were also done in the drug group during the study period for any serious adverse effects. After the 2 months of drug therapy, patients showed improvement in the symptoms and signs scoring of Vernal keratoconjunctivitis. There was statistically significant difference between the treatment group at 4th and 8th week. The drugs were well tolerated without any serious adverse effect. Bepotastine besilate ophthalmic solution were found to be effective in alleviating the clinical symptoms and signs of VKC.